What strategic commissioning could mean for the uptake of innovative medicines.

Why attend?

As the NHS accelerates delivery of its long-term ambitions, the way medicines are commissioned is under increasing scrutiny. Traditional budget-led approaches are struggling to support the uptake of innovation at pace—particularly where medicines have the potential to improve outcomes, productivity and system sustainability.

This webinar explores how strategic commissioning offers a powerful reframe: moving from cost containment to affordable, outcome-focused investment in medicines.

Designed for a wide cross-section of the pharmaceutical industry, this session will challenge existing assumptions about access and invite fresh thinking on how industry can work with systems in new, more impactful ways.

What we’ll cover

• What strategic commissioning means when applied to medicines—and why it matters now